In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Review: Clinical Considerations & Payer Perspectives
Late October saw the annual gathering of oncologists and industry in Madrid for ESMO 2023, bringing with it a wave of new clinical results across cancers and a...